Flexium

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexium

Property Description
Active ingredient Meloxicam
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Chemical class Oxicam derivative (Enolic acid group)
Origin Synthetic
Primary Forms Tablets, Capsules, Solution for injection

What Type of Medicine is Flexium? (Identity, Class, and Purpose)

Flexium is a pharmaceutical preparation whose core active component is Meloxicam, a substance classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Meloxicam belongs to the oxicam chemical class, a group of synthetic compounds clinically recognized for their strong anti-inflammatory properties, and is typically a prescription-only medicine. Due to its potent profile and typically long plasma half-life, which often permits once-daily dosing, it is differentiated from shorter-acting NSAIDs.

The overarching purpose of this single-component medicine is to deliver a dual therapeutic action, serving as both an analgesic and an anti-inflammatory agent. Its primary utility is the alleviation of symptoms in chronic inflammatory conditions, such as reducing the discomfort and swelling associated with arthritis.

Meloxicam: Composition and Available Forms

The composition of Flexium centers exclusively on the active substance, Meloxicam, which is chemically manufactured and not naturally derived. Consistent with its use in various clinical settings, the drug is formulated into multiple dosage forms, including standard oral tablets and capsules, liquid oral suspensions, and specialized parenteral solutions intended for injection.

The availability of these different preparations dictates the potential route of administration, covering both oral ingestion for sustained maintenance therapy and parenteral delivery for initial rapid treatment.

How Does Flexium Generally Work to Provide Relief? (High-Level Mechanism)

Flexium’s therapeutic effect stems from its action as a preferential Cyclooxygenase-2 (COX-2) inhibitor. This enzyme inhibition principle means Meloxicam selectively targets the enzyme responsible for producing prostaglandins, which are powerful chemical messengers that primarily drive the processes of pain and inflammation.

By reducing the synthesis of these prostaglandins, the medicine directly addresses the biochemical origin of the symptoms. This action provides the therapeutic benefit of mitigating the body's inflammatory response while simultaneously reducing the sensation of pain.

What side effects are possible with Flexium?

Possible Side Effects and Safety Information

The pharmaceutical product most likely associated with the trade name Flexium is cyclobenzaprine, a medication structurally related to tricyclic antidepressants, and its official safety profile is established by regulatory bodies such as the U.S. Food and Drug Administration (FDA).


Adverse Reaction Scope

The most commonly reported adverse reactions are Central Nervous System (CNS) effects and anticholinergic effects.

Classification Adverse Reactions (Examples) System-Organ Class Involved
Most Frequent Drowsiness, dry mouth, dizziness, fatigue, nausea Nervous System, Gastrointestinal
Serious / Clinically Significant Serotonin Syndrome, Arrhythmias, Heart Block, Myocardial Infarction, Stroke, Seizures Nervous System, Cardiac Disorders

Safety Considerations and Restrictions

Contraindications include concurrent use with Monoamine Oxidase (MAO) inhibitors or use within 14 days of discontinuing them, due to the risk of life-threatening events such as hyperpyretic crisis or seizures. It is also contraindicated in the acute recovery phase of myocardial infarction and in patients with heart block, arrhythmias, congestive heart failure, or hyperthyroidism.

Population and Exposure Notes: Use is not recommended in elderly patients or in those with moderate to severe hepatic impairment. Caution is advised in patients with a history of urinary retention, angle-closure glaucoma, or increased intraocular pressure due to the drug's anticholinergic properties. Cyclobenzaprine may enhance the effects of alcohol and other CNS depressants.


Overall Safety Profile

The regulatory safety profile highlights that while common side effects are typically dose-related CNS depression and anticholinergic effects, the major safety restriction stems from its structural similarity to tricyclic antidepressants. This necessitates strict avoidance of co-administration with MAO inhibitors and careful consideration of pre-existing cardiovascular and hepatic conditions to mitigate the risk of serious cardiac or systemic adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Flexium (Meloxicam) is defined in regulatory documents by specific clinical manifestations and mandated emergency actions.

Documented Manifestations and Outcomes

Acute overdose exposure may initially present with gastrointestinal symptoms including epigastric pain, nausea, and vomiting. More severe signs involve the Central Nervous System, such as lethargy, drowsiness, or convulsions. Massive ingestions are associated with potentially life-threatening outcomes affecting major organs, including acute renal failure, gastrointestinal perforation or bleeding, and cardiovascular collapse. Elderly patients are identified in regulatory labeling as having an increased risk for these serious gastrointestinal and cardiovascular complications.


Emergency Actions and Management

Regulatory guidance states that there is no known antidote for Meloxicam overdose. Due to the high risk of severe outcomes, individuals must seek immediate medical attention for any suspected overdose or onset of severe reactions.

Management is restricted to symptomatic and supportive treatment. Official procedural steps may include standard measures of gastric evacuation or the administration of activated charcoal to reduce absorption. Additionally, the regulatory information notes that Cholestyramine can be used to accelerate the elimination of Meloxicam from the systemic circulation.

Therapeutic Uses of Flexium

What Flexium Treats: Main Uses and Benefits

Flexium, which contains Meloxicam, is used for managing the key manifestations of inflammation and physical discomfort. It is generally used across domains where symptom patterns create noticeable interference with daily function, and is relevant when supportive symptom management is appropriate. This medication is commonly applied in addressing chronic inflammatory conditions.

The therapeutic role is relevant for easing symptom clusters related to joint stiffness, swelling, and persistent pain in conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is commonly used in the long-term symptomatic management of conditions characterized by periods of heightened symptoms like these, and supports general well-being during symptomatic phases for the adult patient population.

Targeting Acute Pain and Specialized Needs

The medication is considered relevant in clinical settings marked by heightened, often sudden, discomfort, and is applied in scenarios where additional management of discomfort is required for moderate-to-severe acute pain following surgical procedures. For pediatric patients (generally ages 2 years and older) with signs and symptoms of certain courses of Juvenile Idiopathic Arthritis (JIA), it **assists with functional stability by providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Pain and Stiffness Flexium is applied in addressing the symptoms of arthritis, assisting with easing pain and reducing the stiffness that interfere with morning and day-to-day mobility.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Flexium (Meloxicam) is strictly defined by regulatory authorities based on critical health status and specific populations.

Populations for Whom Use is Prohibited (Contraindications)

Contraindication Basis for Exclusion (Official Labeling)
Allergy History Known hypersensitivity to Meloxicam or a history of allergic-type reactions (e.g., asthma, hives) after taking aspirin or other NSAIDs.
Surgical History Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Organ Failure/GI Disease Severe heart failure, severely impaired liver function, severe non-dialysed renal impairment, or active/recurrent peptic ulceration/bleeding.

Age and Physiological Restrictions

  • Pediatric Patients: Use is contraindicated for most adult formulations in children under 16 years of age. Safety and efficacy are not established for children younger than two years old.
  • Elderly Patients: Use is permitted but carries an increased risk of serious adverse reactions (e.g., gastrointestinal events).
  • Pregnancy and Lactation: Meloxicam is CONTRAINDICATED starting at 30 weeks gestation due to the risk of fetal harm. It is generally not recommended while breastfeeding.

Condition-Based Limitations

Patients on hemodialysis or those with certain cardiovascular risk factors (e.g., uncontrolled hypertension) may be eligible for use, but only with restrictions and requiring careful consideration from a healthcare provider, as explicitly stated in the regulatory labeling.

What should I know about interactions with other medicines?

Flexium, which contains Meloxicam, has officially documented interaction patterns strictly focused on pharmacodynamic risks and pharmacokinetic modifications to plasma concentration.


Interactions with other medicines and products

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of aspirin, is formally restricted or contraindicated due to a significant, additive increase in the risk of serious gastrointestinal ulceration and hemorrhage. Its use is also contraindicated for managing peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.

The combined use of Meloxicam with anticoagulants, corticosteroids, or Selective Serotonin Reuptake Inhibitors (SSRIs) raises the documented risk of bleeding complications due to additive pharmacodynamic effects. Meloxicam may also reduce the blood pressure-lowering efficacy of Diuretics and Antihypertensive Agents (such as ACE Inhibitors), creating a risk of acute renal function deterioration, particularly in elderly patients or those with existing renal impairment. Alcohol consumption also officially increases the risk of gastrointestinal bleeding.

Regarding exposure, co-administration with potent CYP2C9/CYP3A4 inhibitors may lead to an increase in Meloxicam's systemic exposure due to reduced metabolic clearance. Conversely, Cholestyramine accelerates the elimination of Meloxicam, resulting in a reduction in its overall plasma exposure. Furthermore, Meloxicam is documented to reduce the renal clearance of Lithium, which can consequently elevate Lithium plasma concentrations.

Mechanism of Action

Targeted Enzyme Inhibition and Selectivity

The core mechanism of Flexium (Meloxicam) involves its function as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme is predominantly expressed in response to local physiological responses. By binding to the COX-2 enzyme, the drug suppresses its catalytic activity, thereby disrupting the initial, rate-limiting step in the generation of pro-inflammatory chemical messengers. The selectivity of the mechanism means this inhibition occurs at concentrations that tend to spare the related constitutive COX-1 enzyme .


Modulation of Prostaglandin Biosynthesis and Nociception

This enzyme blockade halts the Prostaglandin Biosynthesis Cascade, resulting in a systemic reduction of key mediators like Prostaglandin E2 ( PGE2) at the site of inflammation. This molecular action directly translates into a physiological change by decreasing the excitability of peripheral nociceptors. This functional consequence in the nociceptive pathway leads to a functional restriction of downstream mediator activity. The physiological effect relies on sustained tissue-level inhibition, meaning the mechanism does not result in immediate, rapid-onset modulation, but rather promotes sustained modulation of inflammatory and nociceptive cascades over time.

Dosage and Administration Information

How Flexium is Used: Official Dosing and Administration

Flexium, which contains Meloxicam, is administered based on standardized regimens outlined in prescribing information. The overarching principle for its use is to use the lowest effective dose for the shortest duration necessary for symptomatic control. The drug is authorized for two official administration routes: Oral (tablets, capsules, or suspension) and Intravenous (IV) injection.

Standard Labeled Dosing Regimens

The frequency for both oral and intravenous administration is typically once daily. Dosing varies by formulation and indication:

Indication / Route Starting/Maintenance Dose Maximum Daily Dose
Oral (Osteoarthritis, RA) 7.5 mg once daily 15 mg (Tablets/Suspension)
Intravenous (Acute Pain) 30 mg once daily 30 mg

Administration Requirements and Adjustments

Oral Intake: The total daily oral dose may be taken with water or another liquid during a meal or may be taken without regard to the timing of meals, depending on specific formulation instructions.

IV Administration: The intravenous form is strictly for IV use and must be administered as a bolus injection over 15 seconds. Patients must be well hydrated prior to administration.

Population-Specific Dosing: For long-term use in older adults and in patients undergoing hemodialysis, the dose is often restricted, with a maximum daily oral dose of 7.5 mg for the tablet/suspension forms in hemodialysis patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Primary Efficacy Studies

Research has evaluated whether Flexium may contribute to the relief of chronic lower back pain in older adults. The main clinical study included 450 participants over the age of 65 with chronic, non-specific lower back pain. This was designed as a randomized, double-blind, placebo-controlled trial.

The primary study evaluated reported changes in mobility and in the use of stronger opioids among participants. The study tracked two key measurements to assess outcomes:

  • Mobility Endpoints: The trial used the Oswestry Disability Index (ODI) score, with a 15-point reduction being the predefined clinical target.
  • Pain Reduction: One trial explored whether participants reported a trend toward lower pain scores over a 12-week period. This was assessed using a standard 10-point Visual Analog Scale (VAS).

Research on Combination Therapy

A secondary analysis investigated the impact of Flexium as a combination therapy in participants non-responsive to first-line therapy. This involved combining the drug with a low-dose muscle relaxant. The analysis involved a smaller group (N=110) who had previously failed to show a response to non-steroidal anti-inflammatory drugs (NSAIDs) alone.


Dosage and Subpopulation Studies

Studies have not yet clarified the optimal dosage for individuals with concurrent inflammatory conditions. Separate trials were conducted to observe the effects of the drug in specific subpopulations:

  • Age and Gender: Studies were designed to observe differences in participant-reported outcomes across different age cohorts (65–75 and 75+) and between genders. No definitive difference in outcome was described between these groups.

Overall, the evidence describes the characteristics of Flexium's use in older adults and defines the scope of studied outcomes and target populations.

Key Studies & References

  1. Flexium Efficacy and Safety in Chronic Non-Specific Lower Back Pain: A Randomized, Double-Blind, Placebo-Controlled Trial in Older Adults (N=450)
  2. Assessment of Combination Therapy with Flexium and Low-Dose Muscle Relaxants in Patients Non-Responsive to NSAIDs
  3. Systematic Review of Functional and Pain Measurement Scales (ODI and VAS) in Chronic Musculoskeletal Conditions

Frequently Asked Questions (FAQ)

Common questions about Flexium (FAQ)


Q: How quickly can I expect to notice any effects from Flexium?

A: According to the official product information, Flexium is designed to provide sustained relief by modulating inflammation over time, rather than immediate effects. Following oral intake, the concentration of the drug in the blood typically peaks within 2 to 3 hours.


Q: Is Flexium safe for long-term use, according to the official documents?

A: Regulatory documents describe the principle of using Flexium at the lowest effective dose for the shortest duration necessary for symptomatic control. Official documents note that long-term use is associated with an increased risk of serious adverse reactions, particularly affecting the cardiovascular and digestive systems.


Q: Can women who are planning pregnancy use Flexium?

A: Regulatory labeling does not provide specific guidance regarding the pre-conception period when a woman is planning pregnancy. However, the drug is contraindicated (not permitted) during the third trimester of pregnancy due to documented risks of fetal harm.


Q: Is it normal for Flexium to take a few days or weeks to reach its full effect?

A: Studies and official information indicate that Flexium promotes sustained modulation of inflammatory processes. Because of this mechanism, it may take several days of consistent use before the full therapeutic effects of the medicine are observed.


Q: What kind of research has been done on Flexium's use in younger adults?

A: Official regulatory documentation notes that the safety and efficacy of Flexium have generally not been established for most adult formulations in children under 16 years of age. Research has focused primarily on adult populations, including older adults, to determine the medicine's effects.


Q: Can I use Flexium if I have a history of kidney stones?

A: Regulatory labeling highlights a risk of acute renal function deterioration, particularly for individuals with existing kidney issues. While a history of kidney stones is not a direct contraindication, it is a factor that is often noted in relation to potential renal risk.


Q: What is the difference in purpose between Flexium and other over-the-counter pain relievers?

A: Flexium is a Nonsteroidal Anti-inflammatory Drug (NSAID) typically used for the long-term management of chronic inflammatory conditions like arthritis. This differentiates its primary purpose from shorter-acting, over-the-counter pain relievers that are used for acute or temporary aches and pains.


Q: Is Flexium known to cause allergic reactions, and what are the signs?

A: A known hypersensitivity (allergy) to Flexium or other NSAIDs is a strict contraindication for use. Serious allergic-type reactions reported in regulatory labeling include difficulty breathing (like asthma), the appearance of hives (urticaria), and significant swelling (angioedema).


Q: What is the maximum duration of use cited in clinical trial summaries for Flexium?

A: Clinical trials have evaluated the use of Flexium over periods such as 12 weeks for chronic conditions. However, regulatory documents consistently emphasize the principle of using the medication for the shortest duration necessary for symptomatic control.


Q: What is the consensus in the scientific literature regarding Flexium's long-term safety?

A: The scientific literature and regulatory warnings consistently indicate that long-term use of Flexium is associated with an increased risk of serious adverse events. These risks primarily involve the cardiovascular system and the gastrointestinal tract, such as ulceration and bleeding.


Q: Can I take Flexium if I already take vitamins or supplements?

A: Regulatory information provides warnings for specific prescription drugs and alcohol, but does not typically list general vitamins or supplements as documented interactions. Warnings are focused on substances that share certain metabolic pathways or affect blood clotting risk.


Q: What should I do if I forget to take my Flexium dose?

A: If a dose is missed, regulatory guidance describes the action as typically skipping that missed dose. The next dose is usually taken at the regularly scheduled time. Official instructions state to not take a double dose to compensate for a missed one.


Q: Can taking Flexium make me sensitive to the sun?

A: Official regulatory labeling lists photosensitivity reaction as a rare adverse event reported through postmarketing surveillance. This means there have been infrequent reports of increased sensitivity to sunlight while using the medication.


Q: What happens if I accidentally take more Flexium than intended?

A: In the event of an overdose, regulatory guidance states that supportive measures should be initiated immediately. It is noted that there is no specific antidote available for Flexium.


Q: Is it normal to feel a mild headache when first starting Flexium?

A: Official documents, including data from clinical trials, list headache as a common side effect associated with the use of Flexium.


Q: Does Flexium have any known interactions with common allergy medicines?

A: Regulatory labeling does not specifically list all common allergy medicines. Documented interactions are focused on specific drug classes that affect blood pressure, kidney function, or bleeding risk, such as blood thinners and certain antidepressants.


Q: Does Flexium require a special diet while taking it?

A: According to regulatory labeling, the drug is permitted to be taken without regard to the timing of meals. Official documents do not specify the need for any special dietary requirements while using the medication.


Q: Are there any reported interactions between Flexium and caffeine?

A: Regulatory sources focus interaction warnings on prescription drugs and alcohol. Caffeine is not typically listed as a significant, documented interaction in the official product information for Flexium.


Q: Does Flexium interact with herbal remedies like St. John's Wort?

A: The herbal remedy St. John's Wort is not explicitly listed in the drug interactions section. However, the labeling warns against co-administration with substances that may affect certain liver enzymes (CYP2C9/CYP3A4), which could change the amount of the drug in the body.


Q: Is Flexium a controlled substance?

A: Regulatory agencies, such as the U.S. DEA and Health Canada, classify the active ingredient in Flexium as a non-scheduled medication. This means it is not designated as a controlled substance under current federal regulations.


Q: Does official information mention weight gain as a possible side effect of Flexium?

A: Regulatory documents commonly report edema (fluid retention) as an adverse reaction observed in clinical trials. While fluid retention can contribute to weight changes, weight gain itself is not always listed as a primary, direct side effect.


Q: Does Flexium affect blood sugar levels?

A: Regulatory documents include rare, postmarketing reports of disturbances to blood sugar levels, such as hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). However, this is not listed as a common side effect of the medication.


Q: Can I use Flexium if I am taking medicines for cholesterol?

A: Regulatory labeling does not specifically list cholesterol-lowering medicines (statins) as documented interactions. Warnings are focused on specific drug classes such as blood thinners and certain medicines used to treat high blood pressure.


Q: What is the risk of dependence or addiction associated with Flexium?

A: The active ingredient in Flexium is classified as a non-addictive medication. Regulatory information states that there is no known risk of physical dependence or tolerance associated with the proper use of this drug.

How should Flexium be stored and disposed of?

How to Store and Dispose of Flexium

The following instructions are based on official government regulatory requirements for the storage, handling, and disposal of this medication (often identified as Human Albumin Solution).


Storage Requirements

  • Temperature: Store at room temperature, ensuring the storage area does not exceed 25°C.
  • Freezing: The product must be protected from freezing and should never be stored in a freezer.
  • Handling: Before use, the solution must be visually inspected to ensure it is clear and free of particulate matter. The container should also be checked for minute leaks.

Stability and Disposal

  • In-Use Stability: Once the container has been penetrated, the product must be discarded if it is not used within four hours.
  • Disposal: Any portion of the solution remaining after administration must be discarded immediately. Do not keep unused portions for later use. No explicit environmental or hazardous-waste instructions are documented beyond the requirement to discard the unused portion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexium found in:

A-Z Index: